The concept of LVAD was generally accepted in the 1980s, and various types of LVADs were introduced and put into clinical trials in the mid-1980s, now with the development of a motor pulsation pump with transdermal electromagnetic induction energy, thus achieving a fully built-in LVAD, while miniaturization of the high-energy battery improved the portability of energy, the former reducing the incidence of infection and the latter improving the patient’s quality of life. Some patients are discharged from assistance with gradual improvement of left heart function, and some patients can receive heart transplantation after mating. 1.Characteristics and indications of LVAD LAVD can effectively replace more than 80% of the working capacity of the heart, and the pumping capacity can reach 10 L/min. left heart assist is to introduce blood flow from the left atrium or left ventricle into the assisted pump body, and drive blood flow into the aorta through the pump body, completely replacing the left heart pumping function. It is an ideal treatment for correction of intractable heart failure and prior to heart transplantation. In non-heart transplant patients for the purpose of transitional therapy, LVAD use is indicated when satisfactory surgical correction of malformations or lesions has been completed, metabolic disorders and cardiac electrophysiological abnormalities have been controlled at a more satisfactory level, cardiac pre and post load adjustment and positive inotropic drug applications are ineffective, and when the use of IABP is contraindicated or ineffective, and the patient has difficulty maintaining normal circulation is a prognosis that LVAD should be activated. 2. LVAD device implantation and use The LVAD needs to be implanted with extracorporeal circulation support. The patient’s blood pressure is stabilized between 140/80 and 85/50 mmHg, and then the cardiac signal triggers the controller to regulate the LVAD to synchronize with the left ventricle and reverse pulsation (left ventricular systole, left ventricular diastole, left ventricular systole). The patient’s blood pressure is then stabilized between 140 /80 and 50/50 mmHg. Heparin is used at the beginning of anticoagulation to maintain ACT at 100-200 seconds, and ACT should be controlled at 200-250 seconds for blood pump flow less than 1.5L/min, which can be changed to oral anticoagulants such as Warfarin at a later stage. During the adjuvant period, attention should be paid to insulation, maintenance of effective colloid osmotic pressure, appropriate supplementation of fresh plasma, coagulation factors and platelets, aseptic wound treatment and prevention of infection. complications of LVAD include bleeding, organ thrombosis, air embolism, infection, LVAD failure and right heart failure.